Antibe Therapeutics (TSE:ATE) Sets New 52-Week Low at $0.79

Antibe Therapeutics Inc. (TSE:ATE) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.79 and last traded at C$0.80, with a volume of 83875 shares trading hands. The stock had previously closed at C$0.82.

ATE has been the subject of several research analyst reports. Canaccord Genuity downgraded shares of Antibe Therapeutics from a “speculative buy” rating to a “hold” rating and decreased their price objective for the company from C$5.00 to C$1.50 in a research note on Friday, October 15th. Maxim Group decreased their price objective on shares of Antibe Therapeutics from C$10.00 to C$2.00 and set a “buy” rating for the company in a research note on Wednesday, August 4th. Echelon Wealth Partners restated a “speculative buy” rating on shares of Antibe Therapeutics in a research note on Thursday, October 14th. Raymond James restated an “outperform” rating and issued a C$4.00 price objective on shares of Antibe Therapeutics in a research note on Wednesday, August 18th. Finally, Leede Jones Gab cut shares of Antibe Therapeutics from a “speculative buy” rating to a “hold” rating in a report on Friday, October 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of C$2.50.

The business’s fifty day moving average price is C$1.07 and its 200 day moving average price is C$2.45. The company has a quick ratio of 17.33, a current ratio of 19.00 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of C$40.27 million and a PE ratio of -1.27.

In other Antibe Therapeutics news, Director Walter Minnes Macnee bought 50,000 shares of Antibe Therapeutics stock in a transaction dated Wednesday, November 10th. The stock was acquired at an average cost of C$0.90 per share, with a total value of C$45,000.00. Following the completion of the acquisition, the director now owns 497,027 shares of the company’s stock, valued at C$447,324.30. Insiders bought 90,500 shares of company stock valued at $83,125 over the last ninety days.

Antibe Therapeutics Company Profile (TSE:ATE)

Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

Read More: 52-Week High/Low

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.